Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
176,200 ^KRW	-0.62%		-2.06%	-12.56%

May. 24	Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe	CI
May. 10	Celltrion's Q1 Attributable Profit Slumps 86%	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally	May. 20	AQ
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference	May. 20	AQ
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	May. 16	AQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	Mar. 20	AQ
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)	Mar. 05	AQ
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	Feb. 29	AQ
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47	Feb. 29	AQ
Chugai, Genentech, And Hoffmann-La Roche Dismiss Appeals Of Actemra® Patent IPR Final Written Decisions	Feb. 29	AQ
Updates On Aflibercept BPCIA Litigation	Feb. 19	AQ
Celltrion Launches 80 Mg YUFLYMA (Adalimumab-aaty) In The U.S.	Feb. 05	AQ
PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid	Jan. 26	AQ
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 12	AQ
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation	Jan. 11	AQ
Celltrion Completes Application For FDA Approval Of CT-P41, Biosimilar Of Prolia® / Xgeva®	Jan. 02	AQ
Regeneron Sues Celltrion For Proposed Biosimilar Of Eylea In West Virginia District Court	Nov. 20	AQ
Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb)	23-10-31	AQ
Celltrion Expands Access To YUFLYMA (Adalimumab-Aaty)	23-10-19	AQ
Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Press Releases

Filters